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The molecular basis for p53-mediated tumor
suppression remains unclear. Here, to elucidate
mechanisms of p53 tumor suppression, we use
knockin mice expressing an allelic series of p53 tran-
scriptional activation mutants. Microarray analysis
reveals that one mutant, p5325,26, is severely
compromised for transactivation of most p53 target
genes, and, moreover, p5325,26 cannot induce
G1-arrest or apoptosis in response to acute DNA
damage. Surprisingly, p5325,26 retains robust activity
in senescence and tumor suppression, indicating
that efficient transactivation of the majority of known
p53 targets is dispensable for these pathways. In
contrast, the transactivation-dead p5325,26,53,54
mutant cannot induce senescence or inhibit tumori-
genesis, like p53 nullizygosity. Thus, p53 transactiva-
tion is essential for tumor suppression but, intrigu-
ingly, in association with a small set of novel p53
target genes. Together, our studies distinguish the
p53 transcriptional programs involved in acute
DNA-damage responses and tumor suppression—a
critical goal for designing therapeutics that block
p53-dependent side effects of chemotherapy
without compromising p53 tumor suppression.INTRODUCTION
The facts that over half of all human cancers sustain mutations in
the p53 tumor suppressor gene and that p53 null mice display
a dramatic early-onset, completely penetrant cancer predisposi-
tion together underscore the fundamental importance of p53
for tumor suppression (Kenzelmann Broz and Attardi, 2010;Vogelstein et al., 2000). p53 serves as a cellular stress sentinel,
responding to myriad stresses by restricting cellular expansion
under unfavorable conditions (Vousden and Prives, 2009). The
best characterized p53 functions are in inducing cell-cycle arrest
or apoptosis in response to acute DNA-damage signals. The
ability of p53 to eliminate cells that have encountered acute
genotoxic stress is thought to be an ancestral function, as this
response is conserved through lower eukaryotes, including
Drosophila melanogaster and Caenorhabditis elegans, where it
is critical for culling damaged cells to preserve germline and
tissue integrity (Lu and Abrams, 2006). In higher eukaryotes,
oncogene expression can also activate p53, leading to cellular
senescence or apoptosis as safeguards against neoplasia
(Vousden and Prives, 2009).
The extent to which the ability of p53 to respond to DNA
damage is involved in mediating tumor suppression has been
controversial. Analysis of early human neoplastic lesions has
revealed molecular marks of activated DNA-damage compo-
nents, leading to amodel whereby oncogene-induced hyperpro-
liferation results in replication fork collapse, DNA double-strand
break formation, checkpoint kinase activation, and p53 induc-
tion to ultimately impose a barrier to tumor development (Halazo-
netis et al., 2008). However, studies in mouse models of
DNA-damage-induced lymphomas and fibrosarcomas have
suggested that to serve as a tumor suppressor, p53 responds
not to acute DNA damage but rather to oncogene-induced
expression of the p19ARF tumor suppressor, which directly acti-
vates p53 through sequestration and inhibition of its negative
regulator Mdm2 (Christophorou et al., 2006; Efeyan et al.,
2006). A clearer understanding of the role of DNA-damage-trig-
gered, p53-induced cell-cycle arrest or apoptosis in tumor
suppression would come from elucidating the underlying
molecular mechanisms for p53 action in the contexts of acute
DNA damage versus tumor suppression. Moreover, illuminating
any distinct downstream aspects to these pathways has critical
therapeutic implications, as many of the deleterious side effects
of genotoxic chemotherapies result from p53-driven apoptosisCell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 571
in radiosensitive tissues, and therefore identifying strategies to
mitigate these side effects without compromising tumor
suppressor function throughout the organism would be broadly
valuable for cancer therapy (Gudkov and Komarova, 2003).
The molecular underpinnings for p53 action in tumor suppres-
sion have remained elusive. p53 serves as a transcriptional acti-
vator of numerous target genes, but several other biochemical
activities have also been ascribed to p53 (Green and Kroemer,
2009; Vousden and Prives, 2009). Moreover, no p53 target
gene knockout mouse strain recapitulates the dramatic cancer
predisposition of p53 null mice, illustrating our incomplete
understanding of p53 networks involved in tumor suppression
and suggesting that other pathways could be involved (Lozano
and Zambetti, 2005). Defining the role of transactivation in tumor
suppression by p53 is complicated by the fact that p53 contains
two distinct transcriptional activation domains (comprising resi-
dues 1–40 and 40–83, respectively), whose discrete functions
and relative contributions to p53 function are not understood
(Candau et al., 1997; Venot et al., 1999; Zhu et al., 1998). Parsing
out the specific roles of these two domains for p53 function
in vivo could reveal distinct transcriptional requirements for
acute DNA-damage responses and tumor suppression and
lead to the discovery of p53 target genes principally important
for tumor suppression.
Here, we investigate the mechanism of p53-mediated tumor
suppression and its relationship to acute DNA-damage
responses by deciphering the p53 transactivation requirements
for function in these contexts. We generate a series of transacti-
vation domain (TAD) mutant knockin mouse strains, with alter-
ations in the first, second, and both TADs. Knockin mice, in
which the mutant genes are expressed from the native p53
promoter, uniquely enable the study of both primary cells
ex vivo and tumor development in the physiological context of
the organism. Intriguingly, our studies reveal that different p53
transcriptional activation requirements, associated with different
target gene expression programs, are important in the settings of
acute genotoxic stress and oncogenic stimuli. Our findings
thereby provide genetic evidence that the mechanisms through
which p53 engages responses to these signals are different
and lend fundamental new insight into the networks involved in
p53-mediated tumor suppression.
RESULTS
Generation of p53 TAD Mutant Knockin Mouse Strains
To decipher the discrete roles of the two p53 TADs in DNA-
damage responses and tumor suppression in vivo, we generated
apanel ofp53mutant knockinmousestrainswithalterations in the
first (p5325,26), second (p5353,54), or both TADs (p5325,26,53,54).
L25Q;W26S knockin mice were generated previously, and anal-
ysis of a small set of p53 target genes inmouseembryo fibroblasts
(MEFs) derived from these mice demonstrated compromised
transactivation of these genes, except Bax (Johnson et al.,
2005). Here, we have generated mouse strains bearing either
the F53Q;F54S mutations found to incapacitate the second p53
TAD in vitro, or mutations in both TADs (L25Q;W26S;F53Q;F54S;
Figures 1A–1D) (Candau et al., 1997; Venot et al., 1999; Zhu et al.,
1998). All alleles carried a transcriptional stop element flanked by572 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.LoxPsites (Lox-Stop-LoxorLSL) in thefirstp53 intron toallow reg-
ulatable p53 expression (Figures 1A–1D).
To initially characterize this set of p53 TADmutant proteins, we
cultured homozygous p53LSL-mut MEFs, infected them with
adenoviruses expressing Cre recombinase (Ad-Cre), and
assayed p53 protein levels and localization (Figures 1E–1G).
Using this approach we typically observed over 90% p53
positivity, and in all experiments, we verified widespread p53
expression in the population being examined. Furthermore,
MEFs expressed p53 only after Cre introduction, indicating
effective silencing of the locus by the LSL cassette (Figure 1G),
and allowing us to use MEFs infected with empty adenoviruses
(Ad-empty) as convenient p53 null controls. Although basal
p5325,26 and p5325,26,53,54 protein levels were elevated relative
to wild-type (WT) p53 levels because mutation of residues
25/26 inhibits binding of the Mdm2 ubiquitin ligase (Lin et al.,
1994), protein levels were in a physiological range, accumulating
to levels only slightly higher than those of wild-type p53 after
DNA damage (Figures 1F and 1G). Additionally, p5353,54 basal
levels were slightly increased relative to wild-type p53, consis-
tent with the reported contribution of residues 53/54 to the
p53-Mdm2 interaction (Chi et al., 2005). All mutant proteins dis-
played clear nuclear localization (Figure 1G).
p53 Mutants Display a Range of Transcriptional
Activation Capacities
To delineate the relative contributions of the respective TADs to
overall p53 transactivation function, we examined the activity of
the p53mutants both on a genome-wide scale and quantitatively
at select target genes. Initially, we performed gene expression
profiling experiments using a model for oncogenic Hras
(HrasV12)-driven, p53-dependent senescence in MEFs (Serrano
et al., 1997). By comparing HrasV12;p53 wild-type and
HrasV12;p53 null MEFs using Significance Analysis of Microar-
rays (Tusher et al., 2001), we defined a group of p53-dependent
genes, including numerous established p53 targets such as p21
andMdm2 (Figure 2A). Expression of these genes in the mutant
MEFswas compared by heat map analysis andNorthern blotting
to reveal notable differences in the activities of the threemutants.
First, expression profiles of p5353,54/53,54 cells resembled those
of cells expressing wild-type p53, suggesting that p5353,54
retains p53 transactivation function (Figures 2A and 2B). In
contrast, analysis of p5325,26/25,26 MEFs revealed gene expres-
sion profiles intermediate between those observed in wild-type
and p53 null cells (Figure 2A). To elaborate on this pattern, we
focused on individual established p53-inducible genes, to
ensure analysis of direct p53 targets. This analysis demonstrated
that p5325,26 merely drives extremely low-level expression of
p21, Noxa, and Puma but induces efficient expression of Bax
comparable to wild-type p53, suggesting that p5325,26 is
severely impaired for transactivation of most but not all p53
target genes (Figures 2B and 2D). Finally, the expression profile
of p5325,26,53,54/25,26,53,54 MEFs closely resembled that of p53
null MEFs, suggesting that mutation of both TADs abolishes
transactivation activity (Figures 2A, 2B, and 2D). Chromatin
immunoprecipitation (ChIP) demonstrated that p53 TADmutants
bind p53 target gene promoters in cells, indicating that these
mutations selectively disrupt transactivation function but not
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Figure 1. Generation of p53 TAD Mutant Knockin Mice
(A) Targeting scheme used to generate knockin mice, with the p5325,26,53,54 mutant as an example. Mutant p53 expression from targeted alleles is silenced until
Cre introduction allows for excision of the stop element. Dotted gray lines indicate the sizes of the fragments generated from each allele upon HindIII digestion.
(B) Southern blot showing two correctly targeted, heterozygous ES cell clones compared with a wild-type cell line. Genomic DNA was digested with HindIII and
the Southern blot probed with the 30 external probe indicated in (A).
(C) Sequencing analysis of the reverse complement confirms the presence of point mutations in properly targeted cell lines.
(D) Schematic of p5325,26, p5353,54, and p5325,26,53,54 proteins showing the transactivation domains (TADs), DNA-binding domain (DBD), and oligomerization
domain (OD).
(E) Table summarizing the genotype, treatment, and ultimate functional p53 status of samples used throughout the manuscript. LSL-mut denotes any of the
Lox-Stop-Lox p53 TAD mutants.
(F) Western blot analysis for p53 in wild-type or homozygous p53LSL-mut MEFs transduced with Ad-Cre or Ad-empty (indicated as p53 null), either left untreated
(UT) or treated for 8 hr with 0.2 mg/ml dox (doxorubicin) (8). b-actin served as a loading control. Comparable, high efficiency (>90% of cells) of Cre recombination
was confirmed by immunostaining for p53.
(G) Immunofluorescence for p53 in wild-type or homozygous p53LSL-mutMEFs transduced with Ad-Cre or Ad-empty. Cells were left untreated (left) or treated with
0.2 mg/ml dox to stabilize p53 (right). Nuclei were stained with DAPI.
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Figure 2. Analysis of the Transcriptional Activation Potential of the p53 TAD Mutants
(A) (Upper) Heat map defining transactivation capacity of p53 TADmutants using a p53-dependent gene set identified bymicroarray analysis through comparison
of sixHrasV12;p53wild-type to sixHrasV12;p53 null MEF samples. Columns indicate independent MEF lines. (Lower) Heat map examining p53mutant activity on
confirmed, direct p53 target genes (Brady and Attardi, 2010; Riley et al., 2008).
(B) Northern blot using RNA samples from (A).
(C) ChIP showing that p5325,26,53,54 binds to the p53 response element in the p21 promoter and not to an irrelevant region 3 kb downstream. p16 antibody serves
as a negative control. Values are the averages ± SD of three replicates.
(D) qRT-PCR of RNA from MEFs either untreated (white bars) or treated with 0.2 mg/ml dox for 8 hr (black bars). Graphs indicate averages ± standard error of the
mean (SEM) of quantities normalized first to b-actin and then to wild-type untreated sample values from three independent MEF lines. *Nonsignificant difference
of p > 0.05 versus p53 null.
See also Figure S1.chromatin association (Figure 2C; see Figure S1A available
online). qRT-PCR on DNA-damage-treated MEFs echoed the
microarray results, but emphasized how minimally p5325,26 acti-
vated targets relative to p53 null MEFs and further revealed that
p5325,26,53,54 retained a slight capacity to activateBax (Figure 2D;574 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.Figure S1B). Together, our analyses identify an allelic series of
p53 transactivation mutants that can be used to elucidate the
contribution of different extents of transactivation to p53 bio-
logical function downstream of acute genotoxic and oncogenic
stresses.
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Figure 3. The First p53 TAD Plays the Predominant Role in Acute DNA-Damage Responses
(A) Representative propidium iodide and BrdU flow cytometry data from asynchronous wild-type MEFs showing G1 arrest response after g-irradiation.
(B) Average S phase ratio of g-irradiation-treated/untreated MEFs. Wild-type, p53LSL-25,26/LSL-25,26, p53LSL-53,54/LSL-53,54, and p53LSL-25,26,53,54/LSL-25,26,53,54 cells
were infected with Ad-Cre or Ad-empty and irradiated. Averages of three to five experiments ± standard deviation (SD) are graphed. *Significant difference of
p < 0.001 versus WT p53 one-way ANOVA with Bonferroni post-tests.
(C) p53 immunostaining in p5325,26-expressing small intestine (top) and thymus (bottom) from Rosa26CreER;p5325,26/25,26 mice treated with tamoxifen.
(D) Representative TUNEL-staining images showing apoptotic cells (arrows) in small intestines. Wild-type p53, p53LSL-WT/LSL-WT (WT*), p53LSL-25,26/LSL-25,26,
p53LSL-53,54/LSL-53,54, and p53LSL-25,26,53,54/LSL-25,26,53,54 mice carrying the Rosa26CreERT2 allele were treated with tamoxifen and irradiated, then tissues were
collected 6 hr later. Cre-negative mice treated with tamoxifen served as p53 null controls.
(E) Average number of TUNEL-positive cells per 100 crypts of the small intestine ± SD from at least four mice per genotype. *Significant difference of p < 0.001
versus WT p53, one-way ANOVA with Bonferroni post-tests.
(F) Representative TUNEL staining of thymi, with arrows indicating apoptosis.DNA-Damage-Induced Cell-Cycle Arrest and Apoptosis
Require Full p53 Transcriptional Activity
In the faceof acutegenotoxic stress, p53 triggers either cell-cycle
arrest or apoptosis to limit the propagation of damaged cells. We
first defined transactivation requirements for p53-dependent G1
cell-cycle arrest using a classical MEF model in which cell-cycle
profiles are examined 18 hr after 5 Gy g-irradiation (Kastan et al.,
1992). Whereas wild-type and p5353,54/53,54 cells arrested effi-ciently, both p5325,26/25,26 and p5325,26,53,54/25,26,53,54 cells failed
to arrest, indicating that activity of the first, but not the second,
p53 TAD is essential for DNA-damage-inducedG1 arrest (Figures
3A and 3B). To assess p53 transactivation function in DNA-
damage-triggered apoptosis, we examined p53-dependent
apoptosis in radiosensitive tissues in vivo upon exposure to
ionizing radiation (Lowe et al., 1993; Merritt et al., 1994). Using
Rosa26CreERT2 mice allowed widespread p53 expression inCell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 575
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Figure 4. p5325,26, but Not p5325,26,53,54, Induces Cellular Senescence in HrasV12 MEFs
(A) Average percentages of BrdU-positive cells over time. Left: HrasV12-expressing p53+/+, p53LSL-25,26/LSL-25,26, and p53LSL-25,26,53,54/LSL-25,26,53,54MEFs were
infected with Ad-Cre and cultured. Total percentages of p53-positive cells displaying BrdU positivity are shown. Right: HrasV12-expressing p53+/+, p5353,54/53,54,
and p53LSL-53,54/LSL-53,54 (p53 null) MEFs were cultured and analyzed for BrdU incorporation. The timelines under the graphs denote either days post-Ad-Cre
(performed 4 days afterHrasV12 transduction; left) or days afterHrasV12 transduction (right, where Ad-Cre is not used). Averages ±SEM of at least three cell lines
per genotype are graphed.
(B) qRT-PCR analysis of the expression of the senescence-related target genes p21, Pai-1, and Pml in HrasV12 MEFs. Values are the averages ± SD of
3–5 samples in triplicate.
(C) Pml immunostaining of HrasV12 MEFs at the final time points of senescence assays. DAPI stains nuclei.
(D) MacroH2A staining of HrasV12 MEFs at the final time points of senescence assays. DAPI stains nuclei.
(E) Phase contrast images of SA-b-galactosidase staining and morphology of HrasV12 MEFs at the final time points of senescence assays.
See also Figure S2.the small intestine and less efficient expression in the thymus
upon tamoxifen administration (Figure 3C) (Ventura et al., 2007).
Mice homozygous for each p53 allele were exposed to 5 Gy of
whole-body ionizing radiation, and apoptosis in the small intes-
tine and thymus was examined 6 hr later. We found that
p5325,26 failed to promote apoptosis in vivo, consistent with our
previous analyses examining doxorubicin-induced apoptosis in
E1A-MEFs and studies in cultured lymphocytes (Chao et al.,
2000; Johnson et al., 2005; Gaidarenko and Xu 2009) (Figures
3D–3F).Moreover, compoundmutationof bothTADsdidnot alter
this phenotype, as p5325,26,53,54 also failed to induce apoptosis.
In contrast, mutation of the second TAD alone did not greatly
affect p53-dependent apoptosis. Together, these experiments
underscore the vital roles of the first TAD and robust transactiva-
tion for p53 to promote responses to acute DNA damage and
further reveal that the second TAD plays little to no role in these
responses.576 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.Full p53 Transactivation Function Is Dispensable
for Cellular Senescence
To elucidate p53 transactivation requirements in the context of
oncogenic signals, we examined the allelic series of p53mutants
in HrasV12-induced cellular senescence (Serrano et al., 1997).
HrasV12 was expressed in MEFs, and cell-cycle arrest was
assessed by BrdU labeling. As expected, few cells with wild-type
p53 incorporated BrdU, whereas those lacking p53 proliferated
efficiently upon HrasV12 expression (Figure 4A). Interestingly,
both HrasV12;p5325,26/25,26 and HrasV12;p5353,54/53,54 MEFs
underwent a proliferative arrest with time and displayed hall-
marks of cellular senescence, including flattened, enlarged
morphologies and both transcriptional induction of Pml and
widespread Pml nuclear body accumulation (de Stanchina
et al., 2004; Ferbeyre et al., 2000) (Figures 4A–4C and 4E, Figures
S2A and S2B). Additionally, all arresting cells displayed strong
nuclear staining for the histone variant macroH2A, another
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Figure 5. p5325,26 and p5353,54, but Not p5325,26,53,54, Are Potent
Tumor Suppressors
KrasLSL-G12D/+ mice with p53+/+ (n = 9), p53LSL-25,26/LSL-25,26 (n = 6), p53LSL-
53,54/LSL-53,54 (n = 12), p53LSL-25,26,53,54/LSL-25,26,53,54 (n = 13), or p53/ (n = 6)
status were infected intranasally with Ad-Cre at 6–8 weeks, and lungs were
collected 12 weeks later.
(A) Whole-mount images of lungs from KrasG12D;p53+/+ and KrasG12D;p53/
mice, with arrows indicating tumors.
(B) Average number of macroscopic lung tumors ±SD inmice of all genotypes.
(C) Average tumor burden, calculated as the ratio of total tumor area to total
lung area on H&E-stained sections, ± SD in mice of all genotypes. *No
significant difference, p > 0.05 versus p53wild-type, **Significant difference of
p < 0.001 versus p53 WT, one-way ANOVA Bonferroni post-tests.
(D) Representative histological sections from lungs of each genotype.indicator of senescence (Kennedy et al., 2010) (Figure 4D). Unlike
their wild-type and p5353,54/53,54 counterparts, however, senes-
cent p5325,26/25,26 cells were negative for SA-b-galactosidase,
another common senescence marker (Dimri et al., 1995),
suggesting that full p53 transactivation potential is essential for
this activity (Figure 4E). Thus, despite being highly impaired for
transactivation of most p53 target genes, including the
senescence-relevant targets p21 and Pai-1 (Brown et al., 1997;
Kortlever et al., 2006) (Figure 4B), p5325,26 can induce senes-
cence in the context of oncogenic signals. This surprising finding
indicates that full p53 transactivation potential is dispensable for
p53 to promote senescence. While either single TAD mutant
alone was able to induce senescence, mutation of both
domains completely reversed this phenotype, as indicated by
the high level of proliferation throughout the time course, the
paucity of Pml bodies, and the absence of macroH2A
staining in HrasV12;p5325,26,53,54/25,26,53,54 cells, mimicking
HrasV12;p53/MEFs (Figures 4A, 4C, and 4D). The observation
that p5325,26,53,54 cannot engage the senescence program indi-
cates that, although the full p53 transactivation program is
dispensable, some limited level of p53 transactivation is required
for promoting senescence. Together, our findings suggest
fundamentally distinct requirements for transcriptional activation
between the acute DNA damage and senescence responses: full
p53 transactivation is paramount for proper p53 action down-
stream of genotoxic stress, in both G1 checkpoint function and
apoptosis, whereas more selective p53 transactivation function
suffices for senescence.
p5325,26 and p5353,54 Are Potent Tumor Suppressors
To identify the mechanisms of p53 action downstream of onco-
genic signals in vivo, we interrogated the contribution of p53
transactivation to tumor suppression. We employed a model for
human non-small cell lung cancer (NSCLC) driven by expression
of oncogenic KrasG12D from its endogenous promoter after
Cre-mediated excision of an upstream Lox-Stop-Lox element
(Jacksonet al., 2001). p53 losspromotes theprogressionof these
Kras-driven lung tumors to more advanced lesions, making this
an optimal system to query the mechanism of p53 action (Jack-
son et al., 2001; Johnson et al., 2001). Cohorts of KrasLSL-G12D/+
mice homozygous for the different p53 alleles were subjected
to intranasal Ad-Cre instillation, and tumor burden was assessed
12 weeks later. KrasG12D/+;p53/ mice exhibited visible tumors
studding the lung surfaces, while lungs from KrasG12D/+;p53+/+
mice appeared grossly normal (Figures 5A and 5B). Additionally,
the average tumor burden was dramatically increased in
KrasG12D/+;p53/ mice compared to KrasG12D/+;p53+/+ mice
(Figures 5C and 5D). Strikingly, KrasG12D/+;p5325,26/25,26 and
KrasG12D/+;p5353,54/53,54 lungs were macroscopically normal
with minimal tumor burden, comparable to KrasG12D/+;p53+/+
lungs (Figures 5B–5D). In marked contrast, KrasG12D/+;
p5325,26,53,54/25,26,53,54 lungs exhibited many macroscopic
lesions and significantly greater tumor burdens than KrasG12D/+;
p53+/+ lungs, indicative of a failure to suppress tumor growth.
p5325,26,53,54 did, however, display minimal tumor suppressor
activity relative to p53-deficiency, potentially reflecting residual
transactivation of genes such as Bax or another p53 activity.
Thus, p5325,26 and p5353,54 retain the ability to suppressKrasG12D-induced lung tumor growth, but combined mutation
of both transcriptional activation domains largely reverses tumor
suppressor activity. The remarkable observation that p5325,26
can suppress tumor growth, despite an inability to efficiently acti-
vate most known p53 target genes, including p21, Puma, and
Noxa, suggests that full transactivation is dispensable for p53
tumor suppressor function, a notion bolstered by our studies in
several tumor models of different lineages (data not shown).
Collectively, our studies unveil an unexpected contribution of
both p53 TADs to tumor suppression and provide an unequivocal
demonstration that transcriptional activation function is critical
for p53 tumor suppression in vivo, albeit in a selective fashion.Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 577
Analysis of p53 TAD Mutants Uncovers Target Genes
Associated with Human Cancer
The striking finding that p5325,26 can efficiently activate only
a small subset of all p53 target genes yet it retains full biological
activity in tumor suppression suggests that target genes effec-
tively induced by p5325,26 may encode components important
for mediating p53 function in tumor suppression. Using our
gene expression data (Figure 2A), we sought to identify genes
robustly activated by p5325,26 that could account for its biological
activity. Toward this end, we identified genes efficiently induced
in cells with a wild-type p53 tumor suppressor phenotype (WT
p53, p5325,26, and p5353,54) relative to cells failing to display
a tumor suppressor phenotype (p5325,26,53,54 and p53 null) and
obtained a list of 130 genes, the vast majority of which are not
known p53 target genes. We first sought to determine if these
p53-dependent geneshad significance in humancancer by using
this signature to predict the p53 status of a set of human breast
cancer samplesof knownp53sequence (Miller et al., 2005). Strik-
ingly, theMEF-derived gene list was able to distinguish p53wild-
type from p53mutant human breast cancers with high efficiency
(80% properly segregated using the k-nearest neighbor algo-
rithm; Figure 6A). Moreover, our p53 signature also effectively
stratified these breast cancer samples according to tumor grade
and patient survival, revealing a strong correlation between our
expression profile reflecting loss of p53 tumor suppressor activity
and both higher-grade tumors and reduced survival (data not
shown; Figure 6B). Together, these findings underscore the rele-
vance of our gene set for human carcinogenesis.
To focus functionally on those genes most relevant to tumor
suppression, we then filtered this p53-dependent 130 gene set
for those genes downregulated in human and mouse cancers
of a variety of types using EBI’s Gene Atlas database
(EFO_0000311 ontology term, downregulated in any organism;
Kapushesky et al., 2009) (Figure 6C). In this manner, we derived
a list of 14 genes (Figure 6D). We validated that these genes dis-
played p53-dependent expression, which was either completely
or partially maintained in cells expressing the p5325,26 mutant
(Figure 6E). The targets identified include genes involved in cell
signaling (Abhd4, Phlda3, and Rgs12), cytoskeletal function
(Crip2, Def6, Kank3, Arap2), and DNA repair (Polk, Mgmt, and
Ercc5; Bugni et al., 2009; Kawase et al., 2009; Liu et al., 2008;
van Ham et al., 2003). Additional genes included Sidt2, an ortho-
log of a C. elegans dsRNA transporter that encodes a lysosomal
protein in human cells (Duxbury et al., 2005; Jialin et al., 2010)
and Ttc28, whose encoded protein interacts with the BRCA1-
containing BRCC complex (Sowa et al., 2009). Notably, Phlda3
was recently described as a p53 target gene encoding an AKT
inhibitor and as frequently deleted in lung tumors, and Mgmt
and Ndrg4 have been reported as tumor suppressor genes
(Kawase et al., 2009; Bugni et al., 2009; Melotte et al., 2009).
To further examine the significance of these genes as potential
p53 tumor suppressor target genes in humans, we tested
whether a subset was induced by p53 in primary human fibro-
blasts. Indeed, we observed robust, p53-dependent upregula-
tion of most genes, except MGMT or TTC28, upon doxorubicin
treatment (Figure 6F). MGMT and TTC28 may be induced by
p53 in other human cell settings, however, as suggested by
the demonstrated binding of human p53 to sites near these578 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.genes in ChIP-PET experiments (Wei et al., 2006), and further
work will be required to examine the direct regulation of these
genes by p53 and the contexts in which it might occur. We
also investigated whether our cohort of genes represent direct
p53 effectors using ChIP. We found that p53 in fact binds to
specific consensus binding sites in the regulatory regions of
these genes, demonstrating that their induction is proximal to
p53 activation (Figure 6G; Figures S3A and S3B). Together, our
studies have identified a cadre of tumor suppression-associated
target genes activated by p53 in both mouse and human cells.
Novel p53 Target Gene Products Display Tumor
Suppressor Activity
Wenext sought to assess the biological contribution of several of
these gene products, representing various functional categories,
to p53 function. We first examined the function of these gene
products in a senescence model through overexpression in
HrasV12;p53/ MEFs. Consistent with a role in DNA methyla-
tion,Mgmtwas localized in the nucleus, whereas Abhd4, Phlda3,
Crip2, and Sidt2 were found in the cytoplasm, in keeping with
functions in signaling, modulation of the cytoskeleton, or lyso-
some biology (Figure 7A). We then focused on effects on cell-
cycle progression through analysis of BrdU incorporation, with
p53 and GFP serving as positive and negative controls, respec-
tively, for cell-cycle arrest. Interestingly, we found that the
different targets showed varying capacities to limit proliferation:
Phlda3, Abhd4, and Sidt2 efficiently inhibited cell cycling, while
Mgmt and Crip2 did not (Figure 7B; Figure S4). These gene
products could similarly restrict cell cycling in p53-deficient
human cancer cells, although their activity depended on the
cell types examined (Figure 7C). These findings suggest that
the activity of these targets is conserved in humans, but in
a cell type-dependent fashion, likely because of the specific
pathways deregulated in these particular cancer cells. The fact
that the observed arrest responses were more moderate than
that seen with p53 is in alignment with the notion that p53
regulates programs of genes that coordinately affect a particular
p53 response (Lozano and Zambetti, 2005). In addition, it is not
surprising that some target gene products fail to show a pheno-
type in this assay, as they likely affect cell-cycle-independent
aspects of tumor suppression. For example, Mgmt plays a key
role in DNA repair (Bugni et al., 2009), while Crip2 localizes to
actin-rich structures, suggesting a role in regulating actin
dynamics or cell migration (van Ham et al., 2003). Together,
our data suggest that p53 may trigger multiple subprograms
that cooperate to promote tumor suppression.
To evaluate the functional contribution of these new p53
targets to tumor suppression, we investigated whether inhibiting
their expression promotes cancer. UsingMEFs transformedwith
the oncoproteins E1A and HrasV12, followed by RNA interfer-
ence to knockdown select individual targets, we examined
tumor growth in immunocompromised mice. shRNAs directed
against GFP or p53 served as negative or positive controls for
tumor growth, respectively. Intriguingly, we observed that
knockdown of Phlda3 and Ttc28 resulted in efficient tumor
growth, while knockdown of Sidt2 and Abhd4 resulted in more
moderate tumor growth, although still enhanced relative to
GFP shRNA controls (Figure 7D). The enhanced tumor growth
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Figure 6. Microarray Analysis to Identify p53 Targets Associated with Tumor Suppression
(A) Gene expression profiles of HrasV12MEFs from p53 genotypes that retain wild-type p53 tumor suppressor activity (WT p53, p5353,54/53,54, and p5325,26/25,26)
were compared with those lacking p53 tumor suppressor activity (p5325,26,53,54/25,26,53,54 and p53 null). Those genes expressed at least 2-fold and 1.5 SDs higher
in the wild-type group relative to the p53 null group were used as a p53 signature to predict p53 status of human breast cancer samples by PCA (Miller et al., 2005;
blue = WT p53, p5353,54, and p5325,26 MEFs, red = p5325,26,53,54 and p53 null MEFs, green = p53WT human breast cancers, pink = p53mut human breast cancers).
(B) Kaplan-Meier curves demonstrate the effectiveness of MEF p53 signature in stratifying human breast cancer samples by patient survival; p = 0.0422, log-rank
test.
(C) Schematic showing approach to identify p53 target genes potentially involved in tumor suppression.
(D) Heat map displaying the 14 genes meeting the filtering criteria described in (C).
(E) qRT-PCR validation showing the average expression levels ± SD of target genes in HrasV12MEFs homozygous forWT p53, p5325,26, or p53 null alleles, after
normalization to b-actin.
(F) Induction of target genes by DNA damage is p53 dependent in GM00011 human fibroblasts. qRT-PCR demonstrates the efficacy of p53 knockdown with p53
shRNA compared to scrambled control shRNA (left) and the p53 dependence of target gene induction after 24 hr of treatment with 0.2 mg/ml dox (right). Values are
the averages of three replicates ± SD.
(G) ChIP for p53 binding to consensus sites in target genes in wild-typeMEFs treatedwith 0.2 mg/ml dox for 6 hr. IgG antibody serves as a negative control. Values
represent the fold enrichment of binding to the p53 consensus site compared to binding to an irrelevant gene desert site and are the average of three replicates ±
SD.
See also Figure S3.observed with diminished expression of any of several of these
novel p53 target genes demonstrates that these genes have
tumor suppressor activity. Thus, collectively these studies define
a critical network of direct p53 target genes that are mediators of
tumor suppression.
DISCUSSION
Here, using an allelic series of p53 transactivation domain
mutant knockin mice, we reveal distinct mechanisms for p53action in the contexts of acute DNA damage and oncogenic
signals. Our findings suggest that the transcriptional activation
function of p53 is fundamental for both pathways, but that there
are qualitative differences in the requirements for transactiva-
tion. p53 responses to acute DNA damage in primary cells rely
on an intact first TAD of p53 as the L25Q;W26S mutations within
this domain severely impair transactivation of most classical p53
targets including p21, Noxa, and Puma, and abrogate activity in
both DNA-damage-induced G1 arrest and apoptosis (Figures 7E
and 7F). These observations suggest that full p53 transcriptionalCell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 579
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Figure 7. Novel p53 Target Gene Products Display Tumor Suppressor Activity
(A) Immunofluorescence indicating localization of HA-tagged proteins expressed in HrasV12;p53 null MEFs.
(B) Quantification of BrdU labeling in HrasV12;p53 null MEFs expressing different target gene products and BrdU-pulsed 24 hr posttransfection. The BrdU
labeling index of HA-positive cells was assessed by immunofluorescence. Values are normalized to the proliferative index of cells expressing HA-GFP, and p53 is
used as a positive control for arrest. Averages ± SD are shown.
(C) Quantification of BrdU labeling in H1299 and Saos2 cells expressing p53 or different target gene products, as described in (B). Averages ± SEM are shown.
(D) Average tumor volumes ± SEM, as a function of time, in Scidmice injected with E1A-HRasV12 transformed MEFs with knockdown of various genes. shGFP
control tumors are indicated by the blue line in each graph and labeled with an asterisk.
(E) Models for p53 action in response to acute DNA damage versus oncogenic signals. p53 responses to acute DNA damage, including apoptosis and cell-cycle
arrest, rely on the activity of the first p53 TAD and robust transactivation of canonical p53 target genes such as p21, Noxa, Puma, and Perp. In contrast, p53
responses downstream of oncogenic signaling in senescence and tumor suppression can be driven by either p53 TAD. A more limited p53 transactivation
program, such as through efficient activation of novel p53 target genes regulated by either the first or second p53 TAD, including Phlda3, Abhd4, and Sidt2, can
account for p53 function in these contexts.
(F) Table summarizing findings described in this entire study. **Minimal transactivation of most, but not all, p53 target genes.
See also Figure S4.activation is essential for responses downstream of acute DNA
damage, a notion consistent with the known requirements of
p21 as well as Puma and Noxa, genes robustly induced by
DNA damage, in G1 arrest and apoptosis, respectively (Lozano
and Zambetti, 2005).
In contrast, we find that p53 responses downstream of onco-
genic signals require more selective p53 transactivation function
governed by both TADs, as both the p5325,26 and p5353,54 single
TAD mutants retain the ability to drive senescence and tumor
suppression, whereas p5325,26,53,54 lacks these activities
(Figures 7E and 7F). Similarly, human p5325,26 can induce
apoptosis in some transformed cell contexts (Baptiste-Okoh
et al., 2008). It is very surprising that p5325,26 retains tumor
suppressor function because of its severely impaired ability to
transactivate most p53 target genes, and these observations
suggest that potent transactivation of a complete set of p53
target genes is dispensable for p53-mediated tumor suppres-
sion. However, our finding that p5325,26,53,54 lacks both transac-
tivation capacity and activity downstream of oncogenic signals580 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.shows definitively that transcriptional activation is critical for
tumor suppression. Analysis of the p5325,26 mutant suggests
that tumor suppressor function could reflectminimal transactiva-
tion of canonical p53 target genes such as p21 and Puma
(Efeyan et al., 2007; Hemann et al., 2004), normal transactivation
of the small subset of genes properly activated by p5325,26, or
collaborative action of both classes of genes. Indeed, the
p53R172P mutant requires p21 to suppress tumor development,
and Puma is critical for suppressing lymphomagenesis in
Em-myc transgenic mice (Barboza et al., 2006; Hemann et al.,
2004). Our identification of a new set of direct p53 target genes
efficiently induced by p5325,26 and associated with p53 tumor
suppression in human cancers suggests compelling additional
candidates involved in mediating p53 tumor suppressor
function. Accordingly, our studies of cell-cycle arrest upon over-
expression of target genes in cultured cells and of tumor growth
upon knockdown of target genes in a fibrosarcoma model
together support roles for Abhd4, Phlda3, and Sidt2 in tumor
suppression. Collectively, our studies thus define novel p53
networks critically linked to tumor suppression. Additionally,
while we have focused on defining the contribution of transcrip-
tional activation by p53 to its function in different settings, our
studies do not preclude other p53 activities being relevant for
p53 function in vivo (Green and Kroemer, 2009).
Of significance, the functional redundancy of the first and
second p53 TADs can explain the lack of TAD mutations in
human cancer. The majority of reported p53mutations in cancer
target the p53 DNA-binding domain, where one amino acid alter-
ation can ablate both p53 DNA binding and transactivation
activity (Brady and Attardi, 2010). Although mutating both
TADs can also severely cripple p53 tumor suppression function,
it is less probable that the four amino acid substitutions required
for loss of function would occur during carcinogenesis.
Because the p53 TADs are inextricably linked to the regions
required for negative regulation by Mdm2, mutating the TADs,
particularly residues 25/26, results in p53 stabilization (Lin
et al., 1994). This coupling of transcriptional activation to protein
stability is a common theme among transcription factors
(Kodadek et al., 2006). However, the findings that the p5325,26
protein retains many activities of wild-type p53, but
p5325,26,53,54 does not, despite both mutants exhibiting similarly
enhanced stability, indicate that the observed phenotypes relate
specifically to transcriptional activation potential rather than
simple stabilization.
These studies open the door for detailed analyses of the
mechanisms of p53 target gene induction during responses to
acute DNA damage and oncogenic signaling. Mutations in key
p53 TAD residues likely compromise critical interactions
between p53 and important cofactors. This notion is supported
by in vitro studies showing that mutation of the first TAD disrupts
interactions with TBP, Taf9, Taf6, CBP, and the TRAP80 com-
ponent of the mediator, mutation of the second TAD perturbs
interaction with the p62 component of TFIIH, and mutation of
both TADs impedes binding to p300 and STAGA (Gamper and
Roeder, 2008 and references therein; Teufel et al., 2007). Our
studies demonstrate that the domains defined in vitro are indeed
essential for transcriptional activation by p53 in vivo and further
expand our understanding by revealing that TADs display selec-
tivity according to context. It may be that activation of genes
important for DNA-damage responses relies on specific cofactor
contacts with the first TAD of p53, whereas activation of genes
involved in tumor suppression requires an alternate cofactor(s)
interacting with both TADs. Future investigation of cofactor
recruitment to different classes of p53 target genes using ChIP
analyses may augment our knowledge of the mechanisms of
p53 transcriptional activation.
Through analysis of p5325,26, a mutant unable to elicit
responses to acute DNA damage, our results indicate that p53
tumor suppressor activity in different tissue types, including
epithelia (this study, unpublished observations), does not rely
on its ability to respond to acute genotoxic insults. These find-
ings are consistent with previous studies indicating that p53-
mediated tumor suppression in DNA-damage-induced
lymphomas and fibrosarcomas is independent of p53’s ability
to trigger a response to acute DNA damage (Christophorou
et al., 2006; Efeyan et al., 2006). However, our findings do not
rule out the possibility that in incipient tumors, p53 may reactto low-level, chronic DNA damage, caused by such factors as
replication stress or telomere attrition, through a different mech-
anism (Halazonetis et al., 2008). The idea that the DNA-damage
pathway downstream of chronic genotoxic stress may be mech-
anistically different from that downstream of acute genotoxic
injury provides a potential resolution to the controversy
regarding the role of DNA-damage signaling in activating p53
in nascent tumors and warrants further investigation.
Our studies elaborating amechanistic distinction between p53
pathways downstream of acute DNA damage and oncogene
expression also have significant implications for improving
cancer therapy. Radiation and chemotherapies can be highly
beneficial for cancer treatment, but at the cost of inducing
p53-dependent deleterious side effects in radiosensitive tissues
(Gudkov and Komarova, 2003). Therefore, identifying a strategy
to selectively inhibit some p53 functions to mitigate the delete-
rious side effects of genotoxic therapeutics, without incurring
increased risk of new cancers, would be broadly valuable for
cancer therapy. An inhibitor of the first p53 TAD, administered
during radiation or chemotherapy treatment of p53 mutant
tumors, could potentially minimize associated pathologies
without compromising p53 tumor suppressor function
throughout the organism. An additional therapeutic application
of our studies is the identification of strategies to restore p53
function in tumors via activation of p53 targets uniquely impor-
tant for tumor suppression, providing a promising new route
for cancer therapy.
EXPERIMENTAL PROCEDURES
Generation and Analysis of Mice
The generation of knockin mice is described in the Extended Experimental
Procedures. p53 mutant strains were crossed to Rosa26CreERT2 and
KrasLSL-G12Dmice (Tuveson et al., 2004; Ventura et al., 2007). For the apoptosis
experiments, 5 mg tamoxifen (Sigma) dissolved in 2% ethanol in corn oil (v/v)
was administered for 2 days by oral gavage, and then mice were X-ray-irradi-
ated 72 hr after the last tamoxifen dose. For the tumor study, mice were intra-
nasally infected with 4 3 107 PFU of Ad-Cre (University of Iowa GTVR) as
described (Jackson et al., 2005) and sacrificed 12 weeks later. All animal
work was done in accordance with Stanford University APLAC.
Cell Culture
Adenoviral infections were performed at an MOI of 100 using adenoviral Cre
or empty (Ad5 Cre, denoted ‘‘Ad-Cre’’ or Ad5 empty, denoted ‘‘Ad-empty,’’
University of Iowa GTVR) for 24 hr. Efficient p53 expression (>90% of cells)
was confirmed by immunofluorescence. The DNA-damage G1 arrest assays
were performed in MEFs infected with Ad-Cre or Ad-empty and irradiated
48h later with 5 Gy of g-radiation using a 137Cs source. 14 hr later, cells
were pulsed with BrdU and prepared for flow cytometry as described (Attardi
et al., 2004). For senescence experiments, retroviral transduction of MEFswith
pWZL-HrasV12 (Serrano et al., 1997) was followed by adenovirus infection
4 days later. For overexpression experiments, MEFs and human cells were
transfected using Fugene6 (Roche) and Lipofectamine 2000 (Invitrogen),
respectively, per manufacturer’s instructions. In all experiments, 4 hr BrdU
pulses (3 mg/ml) were performed at the indicated time points.
Microarray Analysis
Total RNA was isolated from HrasV12 MEFs 48 hr after Ad-Cre or Ad-empty
infection and processed for analysis by Affymetrix Mouse Genome 430 2.0
expression arrays per manufacturer’s instructions. Probe-level data were pro-
cessed using BRB-ArrayTools (Biometric Research Branch of the National
Cancer Institute), with Robust Multichip Average for background adjustment,Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 581
normalization, and expression summarization. All subsequent analysis was
performed using MeV (Saeed et al., 2006).
qRT-PCR, Northern Blotting, and Western Blotting
RNAwas isolated using Trizol (Invitrogen) and reverse transcribed usingMMLV
reverse transcriptase (Invitrogen) and random primers. PCR was performed in
triplicate using SYBR green (SA-Biosciences) and a 7900HT Fast Real-Time
PCR machine (Applied Biosystems), and results were computed relative to
a standard curve made with cDNA pooled from all samples. Northern blotting
was performed as described (Johnson et al., 2005). p53 western blotting was
performed using anti-p53 antibodies (CM5; Vector Labs, 1:1000) and anti-actin
antibodies (Santa Cruz, 1:1000), using standard protocols.
Chromatin Immunoprecipitation
Cells were crosslinked with 1% formaldehyde and neutralized with 0.125 M
glycine. Purified chromatin was sonicated to 500 bp. Immunoprecipitations
were performed with anti-p53 antibodies (CM5; Vector Labs) or IgG or p16
antibodies as controls (Santa Cruz) and washed 53 with LiCl wash buffer
(100 mM Tris [pH 7.5], 500 mM LiCl, 1% NP-40, 1% Na-deoxycholate) and
13 with TE. The ChIP’ed DNA was eluted for 1 hr at 65C in elution buffer
(1% SDS, 0.1 M NaHCO3). After reverse crosslinking the samples, qPCR
was performed in triplicate as described above and compared to a standard
curve of immunoprecipitation input.
Cell and Tissue Staining
Immunofluorescence was performed using standard protocols and the
following antibodies: anti-human p53 (rabbit FL-393; 1:250, Santa Cruz),
anti-HA (rabbit; 1:200, Invitrogen), anti-mouse p53 (rabbit CM5; 1:150, Vector
Labs), anti-PML (mouse; 1:100, gift of S. Lowe), and anti-BrdU (mouse; 1:50,
BD Biosciences). Where relevant, cells were costained with p53 and the anti-
body of interest and only p53-positive cells were used in analysis. TUNEL
staining on mouse tissues was performed as described (Ihrie et al., 2003).
Hematoxylin and eosin (H&E) staining of mouse lungs was performed using
standard protocols on paraffin-embedded lung. Lungs were sliced into several
coronal pieces prior to embedding, and H&E sections were analyzed using Bi-
oquant Osteo imaging software (Bioquant), where tumors were manually
circled and quantified to determine area and then divided by the total lung
area, excluding airspace. For SA-b-galactosidase staining, cells were fixed
in 2% formaldehyde/0.2% glutaraldehyde and incubated with X-gal at pH
6.0 for 48 hr as described (Dimri et al., 1995).
ACCESSION NUMBERS
All microarray data are available in the Gene Expression Omnibus (GEO) data-
base (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE27901.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.cell.
2011.03.035.
ACKNOWLEDGMENTS
Microarray analyses were performed using BRB-ArrayTools developed by
Dr. Richard Simon and the BRB-ArrayTools Development Team. We thank
T. Jacks for providing the Rosa26CreERT2 mice, S. Lowe for the pWZL-
HrasV12 plasmid and Pml antibody, S. Artandi for the 3xHA expression
plasmid, and W. Hahn and A. Schinzel and the Dana Farber RNAi facility for
the lentiviral shRNA constructs; D. Burkhart, A. Krieg, J. Sage, and L. Sayles
for technical assistance; and S. Artandi, A. Brunet, A. Giaccia, and J. Sage
for critical reading of the manuscript. This work was supported by a Smith
Stanford Graduate Fellowship to C.A.B., a Lucille P. Markey Biomedical
Research Stanford Graduate Fellowship to T.M.J., National Science Founda-
tion Graduate Research Fellowships to C.A.B. and T.M.J., a Gerald Lieberman582 Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc.Dissertation Fellowship to C.A.B., a C.A.P.E.S Fellowship to S.S.M., a Swiss
National Science Foundation Fellowship to D.K.B., and funding from the
American Cancer Society, the Leukemia and Lymphoma Society, and the
National Institutes of Health (CA140875) to L.D.A.
Received: October 9, 2010
Revised: February 3, 2011
Accepted: March 18, 2011
Published: May 12, 2011
REFERENCES
Attardi, L.D., de Vries, A., and Jacks, T. (2004). Activation of the p53-depen-
dent G1 checkpoint response in mouse embryo fibroblasts depends on the
specific DNA damage inducer. Oncogene 23, 973–980.
Baptiste-Okoh, N., Barsotti, A.M., and Prives, C. (2008). A role for caspase 2
and PIDD in the process of p53-mediated apoptosis. Proc. Natl. Acad. Sci.
USA 105, 1937–1942.
Barboza, J.A., Liu, G., Ju, Z., El-Naggar, A.K., and Lozano, G. (2006). p21
delays tumor onset by preservation of chromosomal stability. Proc. Natl.
Acad. Sci. USA 103, 19842–19847.
Brady, C.A., and Attardi, L.D. (2010). p53 at a glance. J. Cell Sci. 123, 2527–
2532.
Brown, J.P., Wei, W., and Sedivy, J.M. (1997). Bypass of senescence after
disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts.
Science 277, 831–834.
Bugni, J.M., Meira, L.B., and Samson, L.D. (2009). Alkylation-induced colon
tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene
28, 734–741.
Candau, R., Scolnick, D.M., Darpino, P., Ying, C.Y., Halazonetis, T.D., and
Berger, S.L. (1997). Two tandem and independent sub-activation domains in
the amino terminus of p53 require the adaptor complex for activity. Oncogene
15, 807–816.
Chao, C., Saito, S., Kang, J., Anderson, C.W., Appella, E., and Xu, Y. (2000).
p53 transcriptional activity is essential for p53-dependent apoptosis following
DNA damage. EMBO J. 19, 4967–4975.
Chi, S.W., Lee, S.H., Kim, D.H., Ahn, M.J., Kim, J.S., Woo, J.Y., Torizawa, T.,
Kainosho, M., and Han, K.H. (2005). Structural details on mdm2-p53 interac-
tion. J. Biol. Chem. 280, 38795–38802.
Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B., and Evan, G.I.
(2006). The pathological response to DNA damage does not contribute to p53-
mediated tumour suppression. Nature 443, 214–217.
de Stanchina, E., Querido, E., Narita, M., Davuluri, R.V., Pandolfi, P.P.,
Ferbeyre, G., and Lowe, S.W. (2004). PML is a direct p53 target that modulates
p53 effector functions. Mol. Cell 13, 523–535.
Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano,
E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that
identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl.
Acad. Sci. USA 92, 9363–9367.
Duxbury, M.S., Ashley, S.W., and Whang, E.E. (2005). RNA interference:
a mammalian SID-1 homologue enhances siRNA uptake and gene silencing
efficacy in human cells. Biochem. Biophys. Res. Commun. 331, 459–463.
Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S., and Serrano, M.
(2006). Tumour biology: policing of oncogene activity by p53. Nature 443, 159.
Efeyan, A., Collado, M., Velasco-Miguel, S., and Serrano, M. (2007). Genetic
dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression.
Oncogene 26, 1645–1649.
Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe,
S.W. (2000). PML is induced by oncogenic ras and promotes premature
senescence. Genes Dev. 14, 2015–2027.
Gaidarenko, O., and Xu, Y. (2009). Transcription activity is required for p53-
dependent tumor suppression. Oncogene 28, 4397–4401.
Gamper, A.M., and Roeder, R.G. (2008). Multivalent binding of p53 to the
STAGA complex mediates coactivator recruitment after UV damage. Mol.
Cell. Biol. 28, 2517–2527.
Green, D.R., and Kroemer, G. (2009). Cytoplasmic functions of the tumour
suppressor p53. Nature 458, 1127–1130.
Gudkov, A.V., and Komarova, E.A. (2003). The role of p53 in determining sensi-
tivity to radiotherapy. Nat. Rev. Cancer 3, 117–129.
Halazonetis, T.D., Gorgoulis, V.G., and Bartek, J. (2008). An oncogene-
induced DNA damage model for cancer development. Science 319, 1352–
1355.
Hemann, M.T., Zilfou, J.T., Zhao, Z., Burgess, D.J., Hannon, G.J., and Lowe,
S.W. (2004). Suppression of tumorigenesis by the p53 target PUMA. Proc.
Natl. Acad. Sci. USA 101, 9333–9338.
Ihrie, R.A., Reczek, E., Horner, J.S., Khachatrian, L., Sage, J., Jacks, T., and
Attardi, L.D. (2003). Perp is a mediator of p53-dependent apoptosis in diverse
cell types. Curr. Biol. 13, 1985–1990.
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R.,
Jacks, T., and Tuveson, D.A. (2001). Analysis of lung tumor initiation and
progression using conditional expression of oncogenic K-ras. Genes Dev.
15, 3243–3248.
Jackson, E.L., Olive, K.P., Tuveson, D.A., Bronson, R., Crowley, D., Brown, M.,
and Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced
murine lung cancer. Cancer Res. 65, 10280–10288.
Jialin, G., Xuefan, G., and Huiwen, Z. (2010). SID1 transmembrane family,
member 2 (Sidt2): a novel lysosomal membrane protein. Biochem. Biophys.
Res. Commun. 402, 588–594.
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson,
D.A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes
early onset lung cancer in mice. Nature 410, 1111–1116.
Johnson, T.M., Hammond, E.M., Giaccia, A., and Attardi, L.D. (2005). The
p53QS transactivation-deficient mutant shows stress-specific apoptotic
activity and induces embryonic lethality. Nat. Genet. 37, 145–152.
Kapushesky, M., Emam, I., Holloway, E., Kurnosov, P., Zorin, A., Malone, J.,
Rustici, G., Williams, E., Parkinson, H., and Brazma, A. (2009). Gene expres-
sion atlas at the European bioinformatics institute. Nucleic Acids Res. 38,
D690–D698.
Kastan, M.B., Zhan, Q., el-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V.,
Plunkett, B.S., Vogelstein, B., and Fornace, A.J., Jr. (1992). A mammalian
cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in
ataxia-telangiectasia. Cell 71, 587–597.
Kawase, T., Ohki, R., Shibata, T., Tsutsumi, S., Kamimura, N., Inazawa, J.,
Ohta, T., Ichikawa, H., Aburatani, H., Tashiro, F., et al. (2009). PH domain-
only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136, 535–550.
Kennedy, A.L., McBryan, T., Enders, G.H., Johnson, F.B., Zhang, R., and
Adams, P.D. (2010). Senescent mouse cells fail to overtly regulate the HIRA
histone chaperone and do not form robust Senescence Associated Hetero-
chromatin Foci. Cell Div. 5, 16.
Kenzelmann Broz, D., and Attardi, L.D. (2010). In vivo analysis of p53 tumor
suppressor function using genetically engineeredmousemodels. Carcinogen-
esis 31, 1311–1318.
Kodadek, T., Sikder, D., and Nalley, K. (2006). Keeping transcriptional activa-
tors under control. Cell 127, 261–264.
Kortlever, R.M., Higgins, P.J., and Bernards, R. (2006). Plasminogen activator
inhibitor-1 is a critical downstream target of p53 in the induction of replicative
senescence. Nat. Cell Biol. 8, 877–884.
Lin, J., Chen, J., Elenbaas, B., and Levine, A.J. (1994). Several hydrophobic
amino acids in the p53 amino-terminal domain are required for transcriptional
activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes
Dev. 8, 1235–1246.
Liu, J., Wang, L., Harvey-White, J., Huang, B.X., Kim, H.Y., Luquet, S., Pal-
miter, R.D., Krystal, G., Rai, R., Mahadevan, A., et al. (2008). Multiple pathways
involved in the biosynthesis of anandamide. Neuropharmacology 54, 1–7.Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. (1993).
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature
362, 847–849.
Lozano, G., and Zambetti, G.P. (2005). What have animal models taught us
about the p53 pathway? J. Pathol. 205, 206–220.
Lu, W.J., and Abrams, J.M. (2006). Lessons from p53 in non-mammalian
models. Cell Death Differ. 13, 909–912.
Melotte, V., Lentjes, M.H., van den Bosch, S.M., Hellebrekers, D.M., de Hoon,
J.P., Wouters, K.A., Daenen, K.L., Partouns-Hendriks, I.E., Stessels, F., Lou-
wagie, J., et al. (2009). N-Myc downstream-regulated gene 4 (NDRG4):
a candidate tumor suppressor gene and potential biomarker for colorectal
cancer. J. Natl. Cancer Inst. 101, 916–927.
Merritt, A.J., Potten, C.S., Kemp, C.J., Hickman, J.A., Balmain, A., Lane, D.P.,
and Hall, P.A. (1994). The role of p53 in spontaneous and radiation-induced
apoptosis in the gastrointestinal tract of normal and p53-deficient mice.
Cancer Res. 54, 614–617.
Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan,
Y., Hall, P., Klaar, S., Liu, E.T., et al. (2005). An expression signature for p53
status in humanbreast cancer predictsmutation status, transcriptional effects,
and patient survival. Proc. Natl. Acad. Sci. USA 102, 13550–13555.
Riley, T., Sontag, E., Chen, P., and Levine, A. (2008). Transcriptional control of
human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402–412.
Saeed, A.I., Bhagabati, N.K., Braisted, J.C., Liang, W., Sharov, V., Howe, E.A.,
Li, J., Thiagarajan, M., White, J.A., and Quackenbush, J. (2006). TM4 microar-
ray software suite. Methods Enzymol. 411, 134–193.
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997).
Oncogenic ras provokes premature cell senescence associated with accumu-
lation of p53 and p16INK4a. Cell 88, 593–602.
Sowa, M.E., Bennett, E.J., Gygi, S.P., and Harper, J.W. (2009). Defining the
human deubiquitinating enzyme interaction landscape. Cell 138, 389–403.
Teufel, D.P., Freund, S.M., Bycroft, M., and Fersht, A.R. (2007). Four domains
of p300 each bind tightly to a sequence spanning both transactivation subdo-
mains of p53. Proc. Natl. Acad. Sci. USA 104, 7009–7014.
Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of micro-
arrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA
98, 5116–5121.
Tuveson, D.A., Shaw, A.T., Willis, N.A., Silver, D.P., Jackson, E.L., Chang, S.,
Mercer, K.L., Grochow, R., Hock, H., Crowley, D., et al. (2004). Endogenous
oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic
and developmental defects. Cancer Cell 5, 375–387.
van Ham, M., Croes, H., Schepens, J., Fransen, J., Wieringa, B., and Hendriks,
W. (2003). Cloning and characterization of mCRIP2, a mouse LIM-only protein
that interacts with PDZ domain IV of PTP-BL. Genes Cells 8, 631–644.
Venot, C., Maratrat, M., Sierra, V., Conseiller, E., and Debussche, L. (1999).
Definition of a p53 transactivation function-deficient mutant and characteriza-
tion of two independent p53 transactivation subdomains. Oncogene 18, 2405–
2410.
Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault,
L., Newman, J., Reczek, E.E.,Weissleder, R., and Jacks, T. (2007). Restoration
of p53 function leads to tumour regression in vivo. Nature 445, 661–665.
Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network.
Nature 408, 307–310.
Vousden, K.H., and Prives, C. (2009). Blinded by the light: the growing
complexity of p53. Cell 137, 413–431.
Wei, C.L., Wu, Q., Vega, V.B., Chiu, K.P., Ng, P., Zhang, T., Shahab, A., Yong,
H.C., Fu, Y., Weng, Z., et al. (2006). A global map of p53 transcription-factor
binding sites in the human genome. Cell 124, 207–219.
Zhu, J., Zhou, W., Jiang, J., and Chen, X. (1998). Identification of a novel p53
functional domain that is necessary for mediating apoptosis. J. Biol. Chem.
273, 13030–13036.Cell 145, 571–583, May 13, 2011 ª2011 Elsevier Inc. 583
